Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Brief Summary: This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Participants were randomly assigned to either the bevacizumab (10 milligrams per kilogram (mg/kg) intravenously \[IV\] once every 2 week \[q2w\]) or the placebo arm, in combination with radiation therapy (total dose 60 Gray \[Gy\], administered as 2 Gy fractions, 5 days/week) plus temozolomide (75 milligrams per meter squared \[mg/m\^2\] oral administration \[po\] daily) for 6 weeks. After a 4 week treatment break, participants continued to receive bevacizumab (10 mg/kg IV q2w) or placebo, plus temozolomide (150-200 mg/m\^2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment or until disease progression or unacceptable toxicity, whichever occured first. Following the maintenance phase, bevacizumab (15 mg/kg iv every 3 weeks \[q3w\]) or placebo monotherapy continued. The time on study treatment was until disease progression.


Options:
A: Arm Label: Bevacizumab + RT + Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temozolomide, Radiation: Radiation therapy | Arm Label: Placebo + RT + Temozolomide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation therapy, Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + RT + Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + RT + Temozolomide
B: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
C: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control

Answer: A